New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:48 EDTISISIsis CEO says APOC3 data 'really exciting,' NY Times reports
Following the publication of new studies that independently identified mutations in the APOC3 gene that protect against heart attacks, the CEO of Isis Pharmaceuticals, Stanley Crooke, whose company is developing a drug that counteracts the gene, said, "Trust me, these data are really exciting" and called the product "the most important drug" in the company's pipeline, according to The New York Times. Experts see the findings leading to a push to develop drugs that mimic the effect of the mutations, but caution that drug development takes years and that there are no guarantees that new treatments will succeed, the report noted. Shares of Isis are up 4% in pre-market trading following the study publications. Reference Link
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use